Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Trial of Neoadjuvant Cisplatin vs. Doxorubicin/Cyclophosphamide (AC) in Women With Newly Diagnosed Breast Cancer and Germline BrCa Mutations
Brief Summary: This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug, which is cisplatin in this trial, to learn how well it works in treating a specific cancer. "Investigational" means that cisplatin is still being studied for use in this setting and that research doctors are trying to find out more about it-in this case, how effective cisplatin is for treating breast cancer in BRCA mutation carriers. It also means that the FDA has not yet approved cisplatin for your type of cancer. Cisplatin has been approved by the FDA for treatment of other cancers.

The purpose of this study is to evaluate cisplatin, a chemotherapy drug that has been shown to be active in the treatment of women with breast cancer and a BRCA mutation. In this study, we are comparing cisplatin to the standard chemotherapy, doxorubicin and cyclophosphamide ("AC") that you might receive if you did not participate in this study.


Options:
A: Arm Label: Pembrolizumab + Chemotherapy; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Carboplatin, Drug: Paclitaxel, Drug: Doxorubicin, Drug: Epirubicin, Drug: Cyclophosphamide, Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim | Arm Label: Placebo + Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Doxorubicin, Drug: Epirubicin, Drug: Cyclophosphamide, Drug: Placebo, Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab + Chemotherapy | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Pembrolizumab + Chemotherapy, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Pembrolizumab + Chemotherapy, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Pembrolizumab + Chemotherapy, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): Pembrolizumab + Chemotherapy, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Pembrolizumab + Chemotherapy, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Chemotherapy | Intervention Type: BIOLOGICAL; Name: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim; Assigned to Arm(s): Pembrolizumab + Chemotherapy, Placebo + Chemotherapy
B: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Doxorubicin, Drug: Paclitaxel, Drug: Carboplatin, Drug: Veliparib | Arm Label: Arm C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Placebo, Drug: Doxorubicin, Drug: Paclitaxel | Arm Label: Arm B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Doxorubicin, Drug: Paclitaxel, Drug: Carboplatin, Drug: Placebo | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm C | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Veliparib; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm B, Arm C
C: Arm Label: Arm A (observation) (closed to accrual 05/16/2016); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm B (cisplatin or carboplatin); Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Cisplatin | Arm Label: Arm C (capecitabine); Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Arm C (capecitabine) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm B (cisplatin or carboplatin) | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Arm B (cisplatin or carboplatin)
D: Arm Label: Doxorubicin-Cyclophosphamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Doxorubicin | Arm Label: Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Cisplatin | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Doxorubicin-Cyclophosphamide | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Doxorubicin-Cyclophosphamide

Answer: D